• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Clinical reports of PBT for unresectable LAPC patients are


    Clinical reports of PBT for unresectable LAPC patients are extre-mely scarce but clinical outcomes are satisfactory among CCRT reports to this point. To the best of our knowledge, this is the first study to prove the effectiveness of CCRT using Coelenterazine beams by clarifying that high dose administration to tumors leads to improved prognosis for unresectable LAPC patients. We therefore consider that the physical advantages of proton beams can increase the value of radiotherapy in local CCRT treatment strategies for these patients. 
    In conclusion, CCRT using proton beams resulted in longer sur-vival than previously reported CCRT data using photon RT, and high dose irradiation to the primary tumor prolonged LC and OS for unresectable LAPC patients without any severe GI toxicity. PBT is therefore a safe and effective treatment method for these patients.
    Conflict of interest
    The authors express special thanks to all of the staff involved with PBT at University of Tsukuba. This work was supported by Grant-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (15H04901), and also supported by Japan Agency for Medical Research and Development, AMED (15ck0106186h0001). The authors would also like to thank Dr. Bryan J. Mathis of the Medical English Communication Center at the University of Tsukuba for native language revision.
    Appendix A. Supplementary data
    [1] Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2015;45:884–91.
    [2] Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163–72. [3] Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–703. [4] Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology 2015;89:281–7. [5] Takeda Y, Katsura Y, Ohmura Y, Morimoto Y, Ishida T, Motoyama Y, et al. Combination chemotherapy in patients with metastatic or recurrent pancreatic cancer–a single institution experience. Gan to kagaku ryoho Cancer Chemother 2015;42:2360–3.
    [6] Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2016;77:595–603.
    [7] Clinical Guideline for Pancreatic Cancer Revision Comittee. Clinical guideline for pancreatic cancer 2016. J Gastroenterol 2017;114:627–36. [8] Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2’,2’-difluoro-2’-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867–72. [9] Li C-P, Chao Y, Chi K-H, Chan W-K, Teng H-C, Lee R-C, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57:98–104.
    [10] Yamazaki H, Nishiyama K, Koizumi M, Tanaka E, Ioka T, Uehara H, et al. Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000 mg/m2 gemcitabine can be administered using limited-field radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 2007;183:301–6.
    [11] Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Madiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403–13.